261 related articles for article (PubMed ID: 15529575)
1. Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus.
Alecu M; Coman G; Alecu S
Rom J Intern Med; 2000-2001; 38-39():83-8. PubMed ID: 15529575
[TBL] [Abstract][Full Text] [Related]
2. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
[TBL] [Abstract][Full Text] [Related]
4. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
[TBL] [Abstract][Full Text] [Related]
5. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
6. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse.
van Lopik T; Bijl M; Hart M; Boeije L; Gesner T; Creasy AA; Kallenberg CG; Aarden LA; Smeenk RJ
J Rheumatol; 1999 Jan; 26(1):60-7. PubMed ID: 9918241
[TBL] [Abstract][Full Text] [Related]
7. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
8. IL-17 in cutaneous lupus erythematosus.
Tanasescu C; Balanescu E; Balanescu P; Olteanu R; Badea C; Grancea C; Vagu C; Bleotu C; Ardeleanu C; Georgescu A
Eur J Intern Med; 2010 Jun; 21(3):202-7. PubMed ID: 20493423
[TBL] [Abstract][Full Text] [Related]
9. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R
Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636
[TBL] [Abstract][Full Text] [Related]
10. Increased apoptosis of peripheral blood mononuclear cells in patients with perennial allergic asthma/rhinitis: relation to serum markers of apoptosis.
Grzegorczyk J; Kowalski ML; Pilat A; Iwaszkiewicz J
Mediators Inflamm; 2002 Aug; 11(4):225-33. PubMed ID: 12396474
[TBL] [Abstract][Full Text] [Related]
11. Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran.
Sahebari M; Hatef MR; Rezaieyazdi Z; Abbasi M; Abbasi B; Mahmoudi M
Arch Iran Med; 2010 Mar; 13(2):135-42. PubMed ID: 20187668
[TBL] [Abstract][Full Text] [Related]
12. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus.
Wang H; Xu J; Ji X; Yang X; Sun K; Liu X; Shen Y
Cell Immunol; 2005 Jun; 235(2):117-21. PubMed ID: 16226734
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
14. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
15. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha.
Habib HM; Taher TE; Isenberg DA; Mageed RA
Scand J Rheumatol; 2009; 38(2):112-20. PubMed ID: 19110660
[TBL] [Abstract][Full Text] [Related]
16. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE).
Maczynska I; Millo B; Ratajczak-Stefańska V; Maleszka R; Szych Z; Kurpisz M; Giedrys-Kalemba S
Immunol Lett; 2006 Jan; 102(1):79-82. PubMed ID: 16154204
[TBL] [Abstract][Full Text] [Related]
18. High levels of sFas and PBMC apoptosis before and after excision of malignant melanoma--case report.
Alecu M; Coman G; Dănăilă L
Roum Arch Microbiol Immunol; 2002; 61(4):267-73. PubMed ID: 15055260
[TBL] [Abstract][Full Text] [Related]
19. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
20. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis.
Alecu M; Geleriu L; Coman G; Gălăţescu L
Rom J Intern Med; 1998; 36(3-4):251-9. PubMed ID: 10822522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
